



Sociedad Española
de Reumatología -
Colegio Mexicano
de Reumatología

Reumatología Clínica

www.reumatologiaclinica.org



Case Report

Recurrent pericarditis after Covid-19[☆]

David Rodrigo Domínguez,^a Amalia Rueda Cid,^{b,*} Cristina Campos Fernández,^b
Clara Molina Almela,^b Juan José Lerma Garrido,^b M. Dolores Pastor Cubillo^b

^a Servicio de Medicina Interna, Consorcio Hospital General Universitario de Valencia, Valencia, Spain

^b Servicio de Reumatología y Metabolismo Óseo, Consorcio Hospital General Universitario de Valencia, Valencia, Spain

ARTICLE INFO

Article history:

Received 6 May 2021

Accepted 8 July 2021

Available online 20 December 2021

Keywords:

Covid-19

Rheumatoid arthritis

Pericarditis

Biological treatment

Palabras clave:

COVID-19

Artritis reumatoide

Pericarditis

Tratamiento biológico

ABSTRACT

Patient with rheumatoid arthritis who has Covid-19 with recurrent pericarditis debut, differential diagnosis.

© 2021 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.

Pericarditis efusivo-constrictiva recidivante tras COVID-19

RESUMEN

Paciente con artritis reumatoide que tiene Covid-19 con debut de pericarditis recidivante, diagnóstico diferencial.

Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. Todos los derechos reservados.

Introduction

COVID-19 presents principally with respiratory manifestations. Associated reported complications include adult respiratory distress syndrome (ARDS), thromboembolic disease, excessive inflammatory response, and cardiac complications,¹ which may occur without respiratory symptoms.^{2,3} Cardiac complications include myocardial injury, arrhythmias, acute myocarditis, and ventricular dysfunction⁴; in contrast, acute pericarditis is less common^{5,6} and we have not found any cases of recurrent pericarditis associated with COVID-19 in the literature. We present a case of post-COVID-19 recurrent effusive-constrictive pericarditis that was refractory to medical treatment and required pericardiectomy.

[☆] Please cite this article as: Rodrigo Domínguez D, Rueda Cid A, Campos Fernández C, Molina Almela C, Lerma Garrido JJ, Pastor Cubillo MD. Pericarditis efusivo-constrictiva recidivante tras COVID-19. Reumatol Clín. 2022;18:435–436.

* Corresponding author.

E-mail address: rueadacid@yahoo.es (A. Rueda Cid).

Clinical observation

A 45-year-old man with rheumatoid arthritis (RA) of more than 15 years' duration, on treatment with disease-modifying drugs (DMARDs) in combination with biologic therapy since 2013 (the last drugs received were leflunomide and certolizumab, with good clinical control of the disease). He had previously received treatment with etanercept and adalimumab (discontinued due to secondary ineffectiveness). In March 2020, he was admitted for pneumonia and COVID-19 pleuropericarditis (the latter confirmed by reverse transcription-polymerase chain reaction [RT-PCR]) that debuted with general malaise, low-grade fever, dry cough, epigastralgia, vomiting, chest pain, and dyspnoea.

During admission, his usual treatment was discontinued and he improved with treatment as per the COVID-19 protocol (hydroxychloroquine 400 mg/24 h and Kaletra[®]/12 h and azithromycin 500 mg/24 h both of which were administered for 5 days), although a pericardiocentesis was required. On discharge, treatment with hydroxychloroquine 400 mg and prednisone 15 mg was maintained. However, the patient presented new episodes of pericardial

effusion with hospital admission on three different occasions (June 2020, August 2020, and October 2020), without the presence of arthritis or other symptoms. During the episode in June 2020, the pericardial effusion was severe, leading to cardiac tamponade requiring pericardiocentesis. As a result, he was discharged with treatment consisting of baricitinib 4 mg/ day and colchicine 1 mg/ day in addition to his treatment at baseline. When the patient relapsed again (in August 2020), the baricitinib was replaced by anakinra sc 100 mg/day. In both recurrences, sterile pericardial fluid with lymphocyte predominance, adenosine deaminase (ADA), low glucose and protein, SARS-CoV-2 RT-PCR, interferon gamma release assay (IGRA), polymerase chain reaction (PCR), and mycobacterial cultures (Lowenstein Jensen and Bactec MGIT 960®) were negative, with cytology negative for tumour cellularity.

In October 2020, he presented the last recurrence and was admitted again with severe pericardial effusion and signs of cardiac tamponade on transthoracic echocardiography (TTE). The decision was therefore made to perform pericardiectomy surgery following failure of medical treatment with anti-inflammatory drugs (NSAIDs, prednisone, and colchicine) and immunomodulators (baricitinib and anakinra).

Samples of pericardial fluid and pericardial fragments were referred for clinical analysis, microbiology, and pathology. Biochemical analyses again revealed a sterile serohaematic effusion with lymphocyte predominance, low ADA, glucose and protein; cytology, Gram, bacteriological cultures (aerobic, anaerobic, *Nocardia* spp. and mycobacteria), mycobacteria PCR (GenXpert®), and SARS-CoV-2 RT-PCR were all negative. Pathology of the pericardial biopsy revealed chronic fibrosis, negative for congo red staining (to rule out amyloidosis). In addition, active or past infectious causes were ruled out by IGRA TBC and serology for myopericarditis-causing microorganisms (including hepatitis, HIV, cytomegalovirus, measles, varicella, mumps, parotitis, parvovirus, adenovirus, rubella, *Borrelia* spp., *Rickettsia*, *Mycoplasma*, *Salmonella*, *Chlamydia*, and *Treponema*). Prior to surgery, antinuclear antibodies (ANA) were positive (1/160, 1/320) without specificity and with normal complement; in the history, they were negative. IL-6 of 3.64 pg/mL [0.0–6.4] was also requested. ESR, CRP, and procalcitonin in the different analyses were within normal values. Finally, an underlying haematological or neoplastic process was reasonably ruled out by means of CT-CTAP, serum proteinogram, and urine light chains.

Discussion

We believe that immune dysregulation triggered by SARS-CoV-2 infection in patients with rheumatoid arthritis may have predisposed to the development of effusive-constrictive pericarditis. Cases of acute COVID-19 pericarditis treated with anti-inflammatory drugs (NSAIDs, corticosteroids, and colchicine),^{2,3,5,7} anakinra,^{8,9} and pericardiocentesis^{10,11} have been reported in the literature, but we have not found any published cases of failure of the different treatments. Subsequently, the patient's polyarthritis flare-up and the decision was made to continue treatment with baricitinib.

Conclusions

This case highlights the need to maintain a high suspicion for cardiac complications in patients with progressive dyspnoea that changes with posture and a history of COVID-19 infection. Further experience and studies are needed to gain a better clinical and molecular understanding of COVID-19 infection in patients with rheumatological diseases.

Ethical responsibilities

This is a clinical case report and the patient was asked for verbal consent and the patient's acceptance was recorded in the electronic medical record. Nothing outside the scope of standard clinical practice was performed.

Funding

This research did not receive any specific grants from funding agencies in the public, commercial or non-profit sectors.

Conflict of interests

None.

References

1. Centro de Coordinación de Alertas y Emergencias Sanitarias. Información científica-técnica. Enfermedad por coronavirus, COVID-19. Ministerio de Sanidad de España; 2021.
2. Inciardi Rm, Lupi L, Zaccone G, Italia L, Raffo M, Tomasoni D, et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). *JAMA Cardiol.* 2020;5:819.
3. Kumar R, Kumar J, Daly C, Edroos SA. Acute pericarditis as a primary presentation of COVID-19. *BMJ Case Rep.* 2020;13:e237617.
4. Wu L, O'Kane AM, Peng H, Bi Y, Motriuk-Smith D, Ren J. SARS-CoV-2 and cardiovascular 2 de 3 complications: from molecular mechanisms to pharmaceutical management. *Biochem Pharmacol.* 2020;178:114114.
5. Fox K, Prokup JA, Butson K, Jordan K. Acute effusive pericarditis: a late complication of COVID-19. *Cureus [Internet].* 2020;12:e9074 [Accessed 5 December 2020]. Available from: <https://www.cureus.com/articles/35443-acute-effusive-pericarditis-a-late-complication-of-covid-19>
6. Linschoten M, Peters S, van Smeden M, Jewbali LS, Schaap J, Siebelink H-M, et al. Cardiac complications in patients hospitalised with COVID-19. *Eur Heart J Acute Cardiovasc Care.* 2020;9:817–23, 204887262097460.
7. Ortiz-Martínez Y, Cabeza-Ruiz LD, Vásquez-Lozano SH, Villamil-Gómez WE, Rodríguez-Morales AJ. Pericarditis in a young internal medicine resident with COVID-19 in Colombia. *Travel Med Infect Dis.* 2020;37:101863.
8. Karadeniz H, Yamak BA, Özger HS, Sezenöz B, Tufan A, Emmi G. Anakinra for the treatment of COVID-19-associated pericarditis: a case report. *Cardiovasc Drugs Ther.* 2020;34:883–5.
9. Imazio M, Brucato A, Lazaros G, Andreis A, Scarsi M, Klein A, et al. Anti-inflammatory therapies for pericardial diseases in the COVID-19 pandemic: safety and potentiality. *J Cardiovasc Med.* 2020;21:625–9.
10. Hua A, O'Gallagher K, Sado D, Byrne J. Life-threatening cardiac tamponade complicating myo-pericarditis in COVID-19. *Eur Heart J.* 2020;41:2130.
11. Purohit R, Kanwal A, Pandit A, Patel BM, Meininger GR, Brown JJ, et al. Acute myopericarditis with pericardial effusion and cardiac tamponade in a patient with COVID-19. *Am J Case Rep.* 2020;21:e92554.